Key Points:

• In the Phase I APOLLO study, patients without known ASCVD and elevated Lp(a) ≥150nmol/L were treated with a novel siRNA therapy (SLN360) in a single ascending dose study. The primary outcome was degree of Lp(a) reduction at 150 days. Secondary outcomes included assessment of changes in LDL-C, apoB, oxidized LDL, inflammatory markers, plasminogen, and pharmacokinetics.
• Treatment with SLN360 resulted in a persistent 70-80% reduction in Lp(a) at 150 days in the higher dose regimens (300 and 600mg). A 20-30% reduction in LDL-C and apoB was also observed. Further trials are warranted to determine the effect of a multi-dose regimen as well as to determine potential impact on the development of ASCVD.

Continue reading →